Australian Pharmaceutical Briefs About Its Activities in The Investor Presentation

  • Feb 04, 2020 AEDT
  • Team Kalkine

Australian Pharmaceutical Industries Limited (ASX: API) has released its investor presentation where it has provided API’s activities current at the date of the presentation.

In the presentation, the company discussed about its strategies and is confident of the right capability to implement. The leadership of API is focussed on growth opportunities like:

  • Pipeline of Priceline Pharmacies & Clear Skincare clinics.
  • Consumer Brands sales growth from 2HFY2020.
  • Pharmacy Distribution upside from AstraZeneca & Upjohn.

The company has a stringent balance sheet management and strong cash generation. New Sydney DC investment was of $50 million to offer a leading-edge distribution capability.




All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK